Errata: Effectiveness and Adverse Events of Tolvaptan in Octogenarians With Heart Failure

DOI DOI Web Site PubMed PubMed 被引用文献15件 参考文献16件 オープンアクセス

書誌事項

タイトル別名
  • Effectiveness and Adverse Events of Tolvaptan in Octogenarians With Heart Failure
  • Effectiveness and adverse events of tolvaptan in octogenarians with heart failure. Interim analyses of Samsca Post-Marketing Surveillance In Heart faiLurE (SMILE study)
  • Interim Analyses of Samsca Post-Marketing Surveillance In Heart faiLurE (SMILE study)

この論文をさがす

説明

The vasopressin receptor 2 (V2) receptor antagonist tolvaptan is an aquaretic agent that has been found to improve symptoms in patients with congestive heart failure. In this study (SMILE study), we administered tolvaptan to patients aged ≥ 80 years with heart failure accompanied by congestive symptoms and compared its effectiveness and safety profiles in this group with those in patients < 80 years (U-80). The results showed that the effectiveness of tolvaptan in the aged patients was similar to that in U-80 patients. In the safety profile, the incidence rate of thirst was lower in the aged patients than that in U-80 patients (9.6% versus 11.6%, P = 0.0023). Furthermore, the incidence of hypernatremia, defined as ≥ 150 mEq/L in aged patients, was comparable with that in U-80 patients (2.9% versus 3.6%, respectively, P = 0.3657). Based on these findings, tolvaptan has similar effectiveness and safety profiles in aged patients compared with U-80 patients. In addition, we found that a higher starting dose of tolvaptan was markedly associated with the occurrence of hypernatremia exclusively in the aged population; therefore, we recommend that tolvaptan should be started at lower doses in aged patients.

収録刊行物

  • International Heart Journal

    International Heart Journal 56 (2), 137-143, 2015

    一般社団法人 インターナショナル・ハート・ジャーナル刊行会

被引用文献 (15)*注記

もっと見る

参考文献 (16)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ